Re: BLA 125742/45

COMIRNATY COVID-19 mRNA Vaccine (BNT162/PF-07302048)

Response to CBER 14 March 2022 Information Request (IR) Regarding Additional Reactogenicity Data for Adolescents 12 Through 15 Years of Age

Dear Dr. Marks,

Reference is made to the Biologics License Application (BLA) 125742 for COMIRNATY (COVID-19 mRNA Vaccine) developed by BioNTech and Pfizer for the prevention of COVID-19 caused by SARS-CoV-2 in individuals ≥16 years of age issued on 23 August 2021. Reference is also made to the sBLA to extend licensure of COMIRNATY to adolescents 12 through 15 years of age submitted to BLA 125742 on 16 December 2021.

The purpose of this submission is to respond to CBER 14 March 2022 follow-up IR received via email from Captain Mike Smith, Ph.D., (CBER) to Kathleen Collins (Pfizer Inc.) regarding Pfizer/BioNTech’s response to CBER 07 March 2022 IR submitted to BLA 125742 on 11 March 2022 (Sequence number 0271).

The response to CBER 14 March 2022 IR is provided in Module 1.11.3.

This submission has been scanned for viruses using McAfee VirusScan Enterprise Version 8.8 and is virus free. The submission is being sent via the Gateway.

Should you have any questions regarding this submission, or require additional information, please contact me via phone at (b) (6) or via e-mail at (b) (6).
Sincerely

Kathleen Collins
Senior Director
Global Regulatory Affairs

CC: Ramachandra S. Naik, Ph.D.
CC: Laura Gottschalk, Ph.D.
CC: Captain Michael Smith, Ph.D.